Advanced Filters
noise

Uterine Cancer Clinical Trials

A listing of Uterine Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 235 clinical trials
C Carol Boxtha

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75.

45 - 75 years of age All Phase N/A
M Mirjam Schunk, Dr.med.

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

This study is an open-label, ascending dose phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine

18 - 65 years of age All Phase 1
C CHYI-FENG JAN, MD, PhD

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer<10 mIU/mL) need to take.

20 - 36 years of age All Phase N/A
L Lisa Anderson

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: how well is it working in the liver how does Imdusiran affect the hepatitis B virus Participants will …

18 years of age All Phase 2
R Roel Pieterman

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

The goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question[s] it aims to answer are: How safe is ISA104? Does ISA104 induce immunity against hepatitis B virus? Different doses of the vaccine ISA104 will be administered to participants. These participants are …

18 - 55 years of age All Phase 1/2
P Pongpot Namasae, MD

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Besides affecting the lungs, TB can also impact extrapulmonary organs. Standard TB treatment involves a combination of drugs administered for at least 6 months, but it can cause adverse …

18 - 80 years of age All Phase 4
O Ole Søgaard, Professor, MD, PhD

Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)

Hepatitis B virus (HBV) remains a major global health problem with an estimated 257 million people living with the infection worldwide. Chronic HBV (CHB) is a major cause of liver cirrhosis and hepatocellular carcinoma. While antiviral therapies are available and suppress viral levels, treatment is long-term, does not clear the …

18 - 70 years of age All Phase 1
C Claire McDonell, MS

Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs

The Partner Navigation Intervention Study is a randomized controlled study (RCT) to assess the efficacy and mechanism of action of the first behavioral intervention to increase hepatitis C (HCV) treatment initiation among adult people who inject drugs (PWID).

18 years of age All Phase N/A
N New Zealand Clinical Research

Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.

18 - 75 years of age All Phase 1
L Lu Zhang

Research on Clinical Recovery and Maintenance Strategies for CHB

Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti …

18 - 65 years of age All Phase N/A

Simplify language using AI